Article

Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Volume 68, n° 4S1
page AB15 (avril 2013)
Doi : 10.1016/j.jaad.2012.12.064
Acne

Efficacy and safety of once-daily brimonidine tartrate gel 0.5% for moderate to severe facial erythema of rosacea: Two randomized, double-blind, and vehicle-controlled phase III studies
 

Joseph F. Fowler, MD, University of Louisville, Louisville, KY, United States; Angela Moore, MD, Arlington Center for Dermatology, Arlington, TX, United States; Kappa Meadows, MD, The Education and Research Foundation, Inc, Lynchburg, VA, United States; Mark Jackson, MD, University of Louisville, Louisville, KY, United States; Matthew Leoni, MD, Galderma Research and Development, RNC, Cranbury, NJ, United States; Michael T. Jarratt, MD, DermResearch, Inc, Austin, TX, United States; Terry Jones, MD, J&S Studies, Inc, Bryan, TX, United States


 Supported by Galderma Research and Development, SNC.


Top of the page

© 2013  Published by Elsevier Masson SAS.
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline
You can move this window by clicking on the headline
@@#110903@@